The "HER2-low" nomenclature identifies breast carcinomas (BCs) displaying a HER2 score of 1+/2+ in immunohistochemistry and lacking ERBB2 amplification. Whether HER2-low BCs (HLBCs) constitute a distinct entity is debated.

Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas / E. Berrino, L. Annaratone, S.E. Bellomo, G. Ferrero, A. Gagliardi, A. Bragoni, D. Grassini, S. Guarrera, C. Parlato, L. Casorzo, M. Panero, I. Sarotto, S. Giordano, M. Cereda, F. Montemurro, R. Ponzone, N. Crosetto, A. Naccarati, A. Sapino, C. Marchiò. - In: GENOME MEDICINE. - ISSN 1756-994X. - 14:1(2022), pp. 98.1-98.16. [10.1186/s13073-022-01104-z]

Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas

M. Cereda;
2022

Abstract

The "HER2-low" nomenclature identifies breast carcinomas (BCs) displaying a HER2 score of 1+/2+ in immunohistochemistry and lacking ERBB2 amplification. Whether HER2-low BCs (HLBCs) constitute a distinct entity is debated.
Actionable alteration; Breast cancer; Classification; Gene expression; HER2; HER2-low; Heterogeneity; Mutation; Stratification; Transcriptome; Biomarkers, Tumor; Female; Gene Expression Profiling; Genomics; Humans; Mutation; RNA; Breast Neoplasms; Transcriptome
Settore MED/06 - Oncologia Medica
Settore BIO/11 - Biologia Molecolare
Settore BIO/18 - Genetica
Article (author)
File in questo prodotto:
File Dimensione Formato  
s13073-022-01104-z.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 7.96 MB
Formato Adobe PDF
7.96 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/937129
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 1
social impact